Kilka mniej i bardziej znanych faktów o dydrogesteronie Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2023
Słowa kluczowe:
terapia hormonalna, bolesne miesiączkowanie, wady płodu, zespół napięcia przedmiesiączkowego
##plugins.themes.bootstrap3.article.main##
Abstrakt
Dydrogesteron został wprowadzony do lecznictwa na początku lat 60. XX w. Doczekał się wielu badań potwierdzających swoją skuteczność w licznych wskazaniach, m.in. poronieniu zagrażającym lub nawykowym, dolegliwościach związanych z menstruacją, w leczeniu bezpłodności, objawach endometriozy i terapii hormonalnej objawów menopauzy. Mimo tak dużej ilości informacji wokół tego leku narosło wiele niesprawdzonych przekonań skutkujących nieuzasadnionym ograniczaniem jego stosowania. W niniejszej pracy zostaną one przeanalizowane i zweryfikowane.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Miotła, P. (2023). Kilka mniej i bardziej znanych faktów o dydrogesteronie. Medycyna Faktów , 16(2(59), 177-182. https://doi.org/10.24292/01.MF.0223.08
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Ott J, Egarter C, Aguilera A. Dydrogesterone after 60 years: a glance at the safety profile. Gynecol Endocrinol. 2022; 38(4): 279-87. http://doi.org/10.1080/09513590.2021.2016692.
2. Charakterystyka Produktu Leczniczego. Luteina (access: 21.03.2023).
3. Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum Dev. 2009; 85(6): 375-7.
4. ClinicalTrials.gov. Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI (access: 21.03.2023).
5. Stanczyk FZ, Hapgood JP, Winer S et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013; 34: 171-208.
6. Kurzawa R, Czyżyk A, Kuczyński W et al. Stanowisko grupy ekspertów dotyczące wsparcia fazy lutealnej w przypadku stosowania technik rozrodu wspomaganego (2020) (access: 22.03.2023).
7. Chan DMK, Cheung KW, Ko JKY et al. Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double- blind controlled trial. Hum Reprod. 2021; 36: 587-95.
8. Siew JYS, Allen JC, Hui CYY et al. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage. Eur J Obstet Gynecol Reprod Biol. 2018; 228: 319-24.
9. Atzmon Y, Aslih N, Estrada D et al. Comparable outcomes using oral dydrogesterone vs. micronized vaginal progesterone in frozen embryo transfer: a retrospective cohort study. Reprod Sci. 2021; 28: 1874-81.
10. Ozer G, Yuksel B, Yucel Cicek OS et al. Oral dydrogesterone vs. micronized vaginal progesterone gel for luteal phase support in frozen-thawed single blastocyst transfer in good prognosis patients. J Gynecol Obstet Hum Reprod. 2021; 50(5): 102030.
11. Tomic V, Tomic J, Klaic DZ et al. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015; 186: 49-53.
12. Nadarajah R, Rajesh H, Wong KY et al. Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques. Singapore Med J. 2017; 58(6): 294-7.
13. Tournaye H, Sukhikh GT, Kahler E et al. A phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017; 32(5): 1019-27.
14. Griesinger G, Blockeel C, Sukhikh GT et al. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018; 33: 2212-21.
15. Huang J, Xie Q, Lin J et al. Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin- primed ovarian stimulation protocol for IVF: a retrospective cohort study. Drug Des Devel Ther. 2019; 13: 2553-63.
16. Tausk M. A general summary of dydrogesterone, a derivative of retroprogesterone. Tausk M (ed). International Encyclopaedia of Pharmacology and Therapeutics. Section 48, Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Drugs. Vol. II. Pergamon Press, Oxford, New York 1972: 481.
17. Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol Endocrinol. 2016; 32(2): 97-106.
18. Ikeda T, Suzuki Y, Maeda T et al. Analysis of dysmenorrhea-associated factors and relaxation methods in highschool students. Bosei Eisei. 2011; 52: 129-38.
19. Bernardi M, Lazzeri L, Perelli F et al. Dysmenorrhea and related disorders. F1000Res. 2017; 6: 1645.
20. Taniguchi F, Ota I, Iba Y et al. The efficacy and safety of dydrogesterone for treatment of dysmenorrhea: an open-label multicenter clinical study. J Obstet Gynaecol Res. 2019; 45: 168-75.
2. Charakterystyka Produktu Leczniczego. Luteina (access: 21.03.2023).
3. Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum Dev. 2009; 85(6): 375-7.
4. ClinicalTrials.gov. Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI (access: 21.03.2023).
5. Stanczyk FZ, Hapgood JP, Winer S et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013; 34: 171-208.
6. Kurzawa R, Czyżyk A, Kuczyński W et al. Stanowisko grupy ekspertów dotyczące wsparcia fazy lutealnej w przypadku stosowania technik rozrodu wspomaganego (2020) (access: 22.03.2023).
7. Chan DMK, Cheung KW, Ko JKY et al. Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double- blind controlled trial. Hum Reprod. 2021; 36: 587-95.
8. Siew JYS, Allen JC, Hui CYY et al. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage. Eur J Obstet Gynecol Reprod Biol. 2018; 228: 319-24.
9. Atzmon Y, Aslih N, Estrada D et al. Comparable outcomes using oral dydrogesterone vs. micronized vaginal progesterone in frozen embryo transfer: a retrospective cohort study. Reprod Sci. 2021; 28: 1874-81.
10. Ozer G, Yuksel B, Yucel Cicek OS et al. Oral dydrogesterone vs. micronized vaginal progesterone gel for luteal phase support in frozen-thawed single blastocyst transfer in good prognosis patients. J Gynecol Obstet Hum Reprod. 2021; 50(5): 102030.
11. Tomic V, Tomic J, Klaic DZ et al. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015; 186: 49-53.
12. Nadarajah R, Rajesh H, Wong KY et al. Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques. Singapore Med J. 2017; 58(6): 294-7.
13. Tournaye H, Sukhikh GT, Kahler E et al. A phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017; 32(5): 1019-27.
14. Griesinger G, Blockeel C, Sukhikh GT et al. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018; 33: 2212-21.
15. Huang J, Xie Q, Lin J et al. Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin- primed ovarian stimulation protocol for IVF: a retrospective cohort study. Drug Des Devel Ther. 2019; 13: 2553-63.
16. Tausk M. A general summary of dydrogesterone, a derivative of retroprogesterone. Tausk M (ed). International Encyclopaedia of Pharmacology and Therapeutics. Section 48, Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Drugs. Vol. II. Pergamon Press, Oxford, New York 1972: 481.
17. Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol Endocrinol. 2016; 32(2): 97-106.
18. Ikeda T, Suzuki Y, Maeda T et al. Analysis of dysmenorrhea-associated factors and relaxation methods in highschool students. Bosei Eisei. 2011; 52: 129-38.
19. Bernardi M, Lazzeri L, Perelli F et al. Dysmenorrhea and related disorders. F1000Res. 2017; 6: 1645.
20. Taniguchi F, Ota I, Iba Y et al. The efficacy and safety of dydrogesterone for treatment of dysmenorrhea: an open-label multicenter clinical study. J Obstet Gynaecol Res. 2019; 45: 168-75.